J&J estimated its vaccine price at $5 per dose in the first half of the year and said it would likely be as much as $8 by year end. The healthcare conglomerate, which promised it would not make a profit on the vaccine during the pandemic, said the fluctuating price reflected the net costs of the vaccine and production volumes. The $8 price is a bit lower than previous indications. South Africa has said it is paying $10 per dose for both the J&J and the two-shot Pfizer/BioNTech vaccines. AstraZeneca Plc is charging $3 per shot for its two-dose vaccine.
Category:
Pandemic
Latest
645 children lost their parents to Covid from Apr-May 28 during second wave: WCD
”The scheme, the prime minister has announced, provides support for education and health and will create a corpus of Rs 10 lakh for each child when he or she reaches 18 years of age. This corpus will be used to give a monthly financial support/ stipend form 18 years of age, for the next five years to take care of his or her personal requirements during the period of higher education and on reaching the age of 23 years, he or she will get the corpus amount as one lump-sum for personal and professional use,” Irani said.
Based on audacious assumptions: Centre dismisses studies claiming undercounting of India’s COVID deaths
WHO says people in 20s, 30s, 40s increasingly driving pandemic
“Maybe that’s a good thing to have a virus that is more infectious but less deadly,” Tambyah told Reuters.
Tambyah said most viruses tend to become less virulent as they mutate.
“It is in the virus’ interest to infect more people but not to kill them because a virus depends on the host for food and for shelter,” he said.
“Covid warriors will be first to get vaccinated, once we get it”: MoS Health
Phase 1 and 2 human clinical trials of two of the vaccine candidates, developed indigenously by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR), and Zydus Cadila Ltd, are currently underway.
The Serum Institute of India has been permitted to conduct Phase 2 and 3 human clinical trials of the third vaccine candidate developed by Oxford University. The Pune-based institute has partnered with AstraZeneca for manufacturing the vaccine.
COVID-19:Over 63,000 fresh cases, tally climbs to 25,89,682,death toll nears50k
The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.
ndia has been reporting over 60,000 cases daily since August 7, barring August 11 when the country registered 53,601 new cases of the infection.
The case fatality rate has declined to 1.93 per cent.
There are 6,77,444 active cases of coronavirus infection in the country presently which comprise 26.16 per cent of the total caseload in the country.
USFDA clears simple saliva test for faster detection of COVID-19
With the FDA’s emergency use authorisation, the testing method is immediately available to other diagnostic laboratories that want to start using the new test, which can be scaled up quickly for use across the nation and, perhaps, beyond in the coming weeks, researchers said
”This is a huge step forward to make testing more accessible,” said Chantal Vogels, a Yale postdoctoral fellow, who led the laboratory development and validation along with Doug Brackney, an adjunct assistant clinical professor.
Demand for tech-enabled healthcare solutions rising due to COVID-19 impact: Report
“Consumers are increasingly preferring to have their healthcare needs met remotely or from the comfort and safety of their homes. They expect their healthcare service providers to prioritise adherence to safety protocols,” the report noted.
Coronavirus: Lockdown in Maharashtra will be lifted in stepwise manner: Uddhav Thackeray
“The state government’s ‘Mission Begin Again’ initiative is being implemented step-by-step. The momentum of chase the virus campaign should not stop since the threat of the virus still persists, and monsoon is still active in the state. We have to be careful about rain-related ailments as well,” CM Uddhav Thackeray said.
Milagrow expects 15-20-fold growth in robot sales in FY21 due to Covid-19
The company has its own assembly plant in Gurgaon. Milagrow has provided robots to hospitals like AIIMS, Medanta etc during the lockdown period.
The robotic floor cleaners identify dirt on their own, clean them and move back to their charging point on their own if their battery level goes down.
Obesity raises the risk of death from COVID-19 among men
Obesity and the coronavirus are a dangerous combination for a number of reasons.
Obesity causes restricted breathing, making it more difficult to clear pneumonia and other respiratory infections. Fat is biologically active and a source of pro-inflammatory chemicals, promoting a state of chronic inflammation in the body even before COVID-19 sets in. Obesity causes metabolic changes and abnormalities, even in the absence of diabetes.
65,002 new cases take India”s COVID-19 tally to 25.26 lakh; death toll nearing 50k
There are 6,68,220,active cases of coronavirus infections in the country, which is 26.45 per cent of the total caseload, while the number of recoveries has risen to 18,08,936.
India’s COVID-19 tally had crossed the 20 lakh mark on August 7.
According to the Indian Council of Medical Research (ICMR), 2,85,63,095 samples have been tested up to August 14. Of these, 8,68,679 were examined on Friday, the highest in a day so far.
Of the 996 fresh deaths reported, 364 are from Maharashtra, 117 from Tamil Nadu, 104 from Karnataka, 97 from Andhra Pradesh, 60 from West Bengal, 55 from Uttar Pradesh, 25 from Punjab, 16 each from Bihar, Chhattisgarh and Madhya Pradesh, 15 each from Gujarat and Jharkhand, 13 from Rajasthan, 11 each from Delhi and Jammu and Kashmir and 10 each from Kerala, Odisha and Telangana.
Russia produces first batch of COVID-19 vaccine: Interfax
Some scientists said they fear that with this fast regulatory approval Moscow may be putting national prestige before safety amid the global race to develop a vaccine against the disease.
Russia has said the vaccine, the first for the coronavirus to go into production, will be rolled out by the end of this month.